English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Hepatocellular carcinoma (HCC) is responsible for approximately 90% of primary liver cancers and is the second most common cause of cancer related deaths, worldwide (1). Although it is historically associated with viral infections, the incidence of HCC in western populations is expected to rise due to the increasing prevalence of noncommunicable diseases which are linked to this malignancy. Such diseases include obesity, diabetes, non-alcoholic fatty and alcoholic liver disease (2). There have been recent changes to the available t r e a t m e n t o p t i o n s f o r H C C w i t h c o n c o m i t a n t improvements in outcome of patients with early disease. However, the overall prognosis of HCC remains generally poor, and is correlated with presenting stage. As such, early detection of the disease has been shown to be a significant clinical challenge. A diagnostic marker which has the The value of liquid biopsy in the diagnosis and staging of hepatocellular carcinoma: a systematic review